Wesley D. Fox, MD

Specialties: Family Medicine

Call for an appointment

Current patients connect online through

No Patient Experience Reviews – Why Not?

Gundersen Health System requires a minimum of 30 completed patient surveys in a 12-month period for each clinician before posting a clinician’s rating. Industry best practice is clear that more data provides a more accurate picture of the patient experience.

Main Location

La Crosse Campus
Founders Building - Level 2
1900 South Avenue La Crosse, WI 54601
Office Phone: (608) 775-0375

Fax: (608) 775-6198

Profile

Medical Interests

Comprehensive family medicine, sports medicine and environmental health

Personal Interests

In his free time, you can find Dr. Fox up in his tree stand, in his canoe or checking a National Park off his bucket list.

Languages

English

Education and Training

Medical School

University of Wisconsin School of Medicine

Residency

Gundersen Medical Foundation

Published Works

Fox WD. Long-term micronutrient surveillance after bariatric surgery. 2018
Waller CJ, Cogbill TH, Kallies KJ, et al. Contemporary management of subclavian and axillary artery injuries - a Western Trauma Association multicenter review. 2017
Waller CJ, Cogbill TH, Kallies KJ, et al. Contemporary management of subclavian and axillary artery injuries-A Western Trauma Association multicenter review. J Trauma Acute Care Surg. 2017;83(6):1023-1031. doi: 10.1097/TA.0000000000001645 [doi]
Deng L, Xu-Monette ZY, Loghavi S, et al. Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium. Leukemia. 2016;30(2):361-372. doi: 10.1038/leu.2015.237 [doi]
Dorsey ER, Wagner JD, Bull MT, et al. Feasibility of Virtual Research Visits in Fox Trial Finder. J Parkinsons Dis. 2015;5(3):505-515. doi: 10.3233/JPD-150549 [doi]
Li L, Xu-Monette ZY, Ok CY, et al. Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. Oncotarget. 2015;6(27):23157-23180. doi: 4319 [pii]
Visco C, Li Y, Xu-Monette ZY, et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia. 2012;26(9):2103-2113. doi: 10.1038/leu.2012.83; 10.1038/leu.2012.83
Lubner SJ, Loconte NK, Holen KD, et al. A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2010;9(3):157-161. doi: 10.3816/CCC.2010.n.021
Malik JT, Chih JL, Moller MB, et al. Validation and application of new immunostain alogorithm for molecular subtype classification in diffuse large B-cell lymphoma (DLBCL): An International DLBCL Rituxan-CHOP Consortium Program Study. 2010:Abstract 1902
Descipio C, Schneider L, Young TL, et al. Subtelomeric deletions of chromosome 6p: molecular and cytogenetic characterization of three new cases with phenotypic overlap with Ritscher-Schinzel (3C) syndrome. Am J Med Genet A. 2005;134(1):3-11. doi: 10.1002/ajmg.a.30573 [doi]